Patent Application
20140275864
None.
None.
1. Field of Invention
The present invention relates generally to a wound care dressing and more specifically relates to a bacteriostatic repositionable wound care dressing constructed of a synthetic polymer foam body preferably of polyurethane having a combination biocidal dye with non-oxidant gram-positive and gram-negative characteristics, preferably Methylene Blue and Crystal Violet biocidal dyes bound to the foam. The foam body is secured to an adhesive cover and border made from a plastic film. The foam body ranges from about 1 mm to about 10 mm in thickness and when placed on an open wound, color changes to indicate infection at the wound site.
2. Background of the Invention
There are a number of major problems encountered in present day wound dressings. Such wound dressings are primarily of the cellulose type and the sponge type. Cellulose dressings have probably been used in some form since the beginning of recorded history and are generally constructed of cellulose materials such as cotton. These wound dressings leave linting fibers, allow bacterial growth adjacent the wound and allow wound growth extension into the fibers of the dressing. Removal of the dressing also causes tearing of the wound when the dressing is removed and can leave fibrous fragments in the wound. Because of the fiber spacing in such dressings they also do not present a barrier against direct exposure to air and organisms carried in the air. These wound dressings also do not provide a color change allowing a nurse or technician to observe infection at the wound site.
Advances in the development of synthetic polymers have produced numerous changes in wound care dressings resulting in polymeric foams, polymeric films, particulate and fibrous polymers, hydrogels and hydrocolloids. These developments have resulted in sponge type dressings being widely used but unfortunately these dressings also suffer from wound growth into the cells of the sponges, failure to kill bacteria and other infectious agents, lack of absorption and wound tearing problems which occur when the dressings are removed.
Polyvinyl acetal and polyurethane sponges have been used in the treatment of wounds for many years and have an excellent safety record. Both polymers absorb liquid into the sponge where all bacteriostatic activity takes place.
U.S. Pat. No. 4,098,728 issued Jul. 4, 1978 discloses the use of polyvinyl acetal material having a fast wicking and high liquid holding capacity for medical usage.
U.S. Pat. No. 5,071,648, issued on Dec. 10, 1991 discloses a polyvinyl acetal material with a complex of iodine which forms a sponge releasing controlled amounts of iodine sufficient to kill germ cells with minimum toxicity to the surrounding tissue. Likewise, U.S. Pat. No. 5,744,150 issued on Apr. 28, 1998 and U.S. Pat. No. 5,928,665 issued Jul. 27, 1999 disclose a method for producing an antimicrobial iodine polyvinyl acetal sponge which is soaked in an aqueous bath of 20% to 70% triethylene glycol. The resultant product is a wound dressing including an iodine complexed polyvinyl acetal sponge material in which alkylene glycol is applied to the surface of the sponge to soften the sponge and impart a yellow-gold coloration onto the outer surface of the sponge indicating the activation of the antimicrobial elements complexed in the sponge material.
U.S. Pat. No. 5,810,755 issued Sep. 22, 1998 discloses a medicated wound dressing with an open cell foam polymeric compound of polyvinyl alcohol complexed with elemental iodine. None of these references exhibit a color change of the wound dressing indicating infection at the wound site.
U.S. Pat. No. 5,554,659 issued Sep. 10, 1996 and U.S. Pat. No. 5,556,391 issued Sep. 17, 1996 are directed toward a molded porous polyvinyl alcohol sponge including an outer skin having an average pore size smaller than the interior portion of the product capable of absorbing and passing water to the interior portions of the sponge.
U.S. Pat. No. 5,811,471, issued Sep. 22, 1998 discloses a polyvinyl acetal polymer sponge which has a germicidal disinfectant dye bound thereto which is used as a tampon while U.S. Pat. No. 5,447,505 issued Sep. 5, 1995 discloses the use of polyvinyl acetal sponge surgical dressing. U.S. Pat. No. 6,183,764 issued Feb. 6, 2011 and U.S. Pat. No. 6,361,786 issued Mar. 26, 2002 are also directed toward a polyvinyl acetal polymer material which have a plurality of organic dyes absorbed therein to provide microbiocidal properties.
U.S. Pat. No. 6,613,347 issued Sep. 2, 2003 is directed toward a polyvinyl acetal sponge with a low durometer silicone smooth outer skin having less porosity then the foam center. The composite wound dressing allows moisture adsorption through the skin into the PVA sponge body but presents an outer surface precluding wound growth into the sponge material.
One problem with polyvinyl acetal sponge material is that it should be hydrated before use to soften the sponge.
None of the aforementioned prior art references are directed toward repositionable bacteriostatic gamma irradiated or electron beam sterilized wound dressings which exhibit color change when in contact with the wound to indicate if the site is infected. Bacteriostatic dressings better manage bioburden which helps the body's own immune system restore bacterial balance. The present inventive wound dressing changes its base color to white as an indicator that the wound site is infected and sustains bacteriostatic activity for up to 7 days.
The present invention is directed toward a sterilized polyurethane foam wound care sponge dressing having a thickness ranging from about 1 mm to 10 mm with a cover and border made of a plastic film with a hydrogel adhesive which allows the dressing to be repositionable. The polyurethane sponge is washed and prepped with alcohol to open up the binding sites and then placed into a dye bath containing a gram-negative biocidal Methylene Blue dye and a gram-positive Crystal Violet dye which bind to the open sites of the polyurethane foam material. The sponge foam is rinsed until the unbound dye is removed from the sponge body and dried. An outer adhesive cover and boundary plastic skin is secured to the outer surface of the sponge. The composite wound dressing allows moisture adsorption into the polyurethane sponge body causing the dressing to expand preventing wound leakage and turns to white from its original blue color indicating infection at the wound site.
It is an object of the invention to provide a wound care dressing having an outer adhesive surface of different material from the body of the dressing allowing the dressing to be repositioned on a patient's body.
It is also an object of the invention to provide a wound care dressing where all germicidal activity takes place within the structure of the foam sponge.
It is yet another object of the invention to provide a wound care dressing which will not show a zone of inhibition beyond the contact area of the sponge.
It is still another object of the invention to provide a wound dressing which allows comfortable easy application of the dressing to the wound without hydration and repositioning of the dressing on the wound with minimal tearing of the wound area.
It is another object of the invention to provide a wound dressing which applies a biocidal material covering a full bacteria spectrum at a wound site.
It is yet another object of the invention to provide a wound dressing which exhibits a color change when the wound site is infected.
In the accompanying drawings, there is shown an illustrative embodiment of the invention from which these and other objectives, novel features and advantages will be readily apparent.
These and other objects, advantages, and novel features of the present invention will become apparent when considered with the teachings contained in the detailed disclosure along with the accompanying drawings.
The best mode and the preferred embodiment of the novel wound care dressing is shown generally in
Alternatively, other bactericidal dyes such as gram negative Dimethyl Methylene Blue (blue color); gram negative New Methylene Blue (blue color); gram positive Brilliant Green (green color); gram positive Malachite (green color); gram positive Acriflavine (orange color) and gram positive Quinacrine (yellow color) may be added in the same gram weight noted above, namely 0.00035 g/g or less as long as one dye is gram positive and the other dye is gram negative so that the full spectrum of bacteria and other microbial entities can be acted upon. It has been found that when the aforementioned dyes are added to the polyurethane foam at a concentration ranging from 0.0001 to 0.00035 g/g weight provides a complete biocidal effect throughout the bacterial spectrum and the combination of gram positive and gram negative dyes respectively act on the full spectrum of bacteria.
While the action of the dyes on bacteria is not fully known it is believed that when the dyes come in contact with proteins within bacteria cells they detach from their polymer binding site and enter the cell. Inside the cell it is believed that the dyes may interrupt the electrical pathway of the cell preventing it from reproducing. In short it is theorized that the dyes operate by “short circuiting” electron transport pathways. Various dyes show differential activity towards gram-negative versus gram-positive bacteria and also bind differently to different polymers.
No oxidizing dyes or oxidizing materials such as silver oxide should be added to the foam material as the shelf life and biocidal effectiveness of the foam material will be compromised.
The outer adhesive used on the cover and border 14 around the foam body 12 can be made of medical grade adhesive preferably hydrogel. The body 12 of the polyurethane foam ranges from 1 mm to 10 mm in thickness, preferably 5 mm.
Polyurethane has been selected because of its ability to be sterilized by gamma irradiation or electron beam without damage to the dressing, its absorbability of fluids, the ability to be treated with microbial materials and because it can absorb shock through the flexible cell structure of the material while retaining shape when placed over a wound. The material is also soft and does not have to be hydrated. The wound care sponge 10 center section of polyurethane wicks fluid from the body wound while the cover and border 14 prevents tissue growth and the adhesive allows ease of repositioning of the wound dressing from the patient.
The base polyurethane material is commercially obtained from RYNEL®, Inc., a manufacturer of polyurethane foam and is designated as 562-B foam. As shown in
The polyurethane sponge body used is a white open-celled sponge, with instantaneous fluid wicking. The formed sheet of polyurethane material is preferably about 5 mm but falls within the range of 1 mm to 10 mm in thickness and the sheet can be cut in a sponge pad length of 6 to 10 inches, with a preferred length of 8 inches and a width of about 2.5 inches to 3 inches preferably 2.75 inches. A 1 mm to 3 mm thickness can be used when it is desired to view the color change on the side opposite the wound site. A plastic film covered border 14 having a hydrogel adhesive is secured to the sponge pad which was previously cut from the processed sheet to a desired size.
Any of a variety of additional substances can be later introduced into the finalized polyurethane dressing washing by soaking or immersing the polyurethane dressing in a solution of the desired substance(s) followed by drying of the polyurethane. Substances which can be readily incorporated in the polyurethane sponge by this or any other suitable manner include antimicrobials and/or antibiotics such as erythromycin, bacitracin, neomycin, penicillin, polymyxin B, tetracycline viomycin, chloromycetin and streptomycins, cefazolin, ampicillin, tobramycin, clindamycine and gentamycin, etc.; amino acids, peptides, vitamins, co-factors for protein synthesis; hormones; synthesizers; enzymes such as collagenase, peptidases, oxidases, etc.; angiogenic drugs and polymeric carriers containing such drugs; biocompatible surface active agents; antigenic agents.
The polyurethane sponge wound dressing when treated with the Methylene Blue and Crystal Violet has been found to be effective against the bacteria MRSA, Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa, Pseudomonas florescens, Escherichia coli, Enterococcus faecalis, VRE, Streptoccoccus pyogenes, Klesbsiella pneumoniae. Proteus mirabilis, Proteus vulgaris, and Enterobacter aerogenes, Bacillus subtilis, Yersinia enterocolitica, Serratia marcescens, Streptococcus pneumoniae, and Yeast, Candida albicans, Candida krusei, and Candida glabrata. The killing activity continues in the dressing until the dyes are used up in the sponge and it turns white. The color of the body 12 of the wound dressing is originally blue and infection at the wound site turns the dressing white. Thus color change in the sponge can act as an indicator when the sponge is lifted to determine if a wound is infected or not. The sponge structure can be sterilized with gamma irradiation or electron beam without degradation of the dressing structure and compromising the dye bactericidal effects.
The principles, preferred embodiments and modes of operation of the present invention have been described in the foregoing specification. However, the invention should not be construed as limited to the particular embodiments which have been described above. Instead, the embodiments described here should be regarded as illustrative rather than restrictive. Variations and changes may be made by others without departing from the scope of the present invention as defined by the following claims:
This is a continuation-in-part application from U.S. patent application Ser. No. 13/507,581 filed Jul. 12, 2012.
